Peripheral Artery Disease Clinical Trial
Official title:
HOme-based moNitORed Exercise for PAD: The HONOR Study
Verified date | January 2018 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the effects of a home-based exercise intervention on walking ability in people with peripheral artery disease. In 200 patients with peripheral artery disease (PAD), the investigators are conducting a randomized controlled trial to determine whether a patient-centered home-based exercise program improves walking ability, physical activity, mobility, pain, and social functioning, compared to a usual care group.
Status | Completed |
Enrollment | 200 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Participants with an ankle brachial index (ABI) = 0.90 will be eligible for participation. 2. Participants with an ABI > 0.90 but = 1.00 who experience a 20% drop in ankle pressure after the heel-rise exercise will be eligible. 3. Participants with an ABI > 0.90 who have medical record evidence of prior lower extremity revascularization for PAD will be eligible 4. Participants with an ABI > 0.90 who have medical record evidence of PAD based on non-invasive vascular laboratory testing or based on angiographic findings will be eligible. Non-invasive vascular laboratory evidence of PAD must be obtained from a vascular laboratory. Exclusion Criteria: 1. Above or below knee amputation, critical limb ischemia, wheelchair confinement, foot ulcer, non-English speaking, significant visual impairment that interferes with walking activity, hearing impairment that interferes with full study participation, unable to return to the medical center or fitness center at the expected visit frequency, or unwilling to use technology required for the intervention. 2. Individuals whose walking is limited by a condition other than PAD. 3. Greater than class II NYHA heart failure or angina. Increase in angina, angina at rest, abnormal baseline stress test. 4. Major surgery including lower extremity revascularization or orthopedic surgery during the prior three months or anticipated in the next nine months. 5. Major medical illness including lung disease requiring oxygen, Parkinson's disease that impairs walking ability, or cancer requiring treatment in the prior two years (potential participants may still qualify if they were diagnosed with non-melanoma skin cancer in the past two years or if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent). 6. Heart attack, stroke, or coronary artery bypass surgery in the last 3 months. 7. Mini-mental status examination score < 23, dementia, or psychiatric illness. 8. Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention 9. Currently enrolled in another clinical trial, exercise trial, or in cardiac rehabilitation. Currently enrolled in a clinical trial or current participation in cardiac rehabilitation or a trial of a therapeutic intervention within the past three months. For a clinical trial of a stem cell or gene therapy intervention, potential participants will be potentially eligible immediately after the final study visit for the clinical trial, so long as s at least six months has passed since the participant received their final treatment in the stem cell or gene therapy study . 10. Deemed a poor candidate for the study or poorly suited for the intervention (at PI discretion). |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University Feinberg School of Medicine | Chicago | Illinois |
United States | Northwestern University feinberg School of Medicine | Chicago | Illinois |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | New York University School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Patient-Centered Outcomes Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Six-Minute Walk Performance at 4.5-month follow-up | In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded. | change from baseline to month 4.5 follow-up | |
Other | Change in Walking Impairment Questionnaire (WIQ) distance and speed and stair-climbing scores between baseline and 4.5 month follow-up | The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed. | change from baseline to month 4.5 follow-up | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Questionnaires | PROMIS Physical Function, PROMIS Pain Interference and PROMIS Ability to Participate in Social Roles and Activities questionnaires will be used to assess patient-reported health status for physical, mental, and social well-being. | change from baseline to month 4.5 follow-up | |
Other | Short-Form 36 (SF-36) physical functioning score | The SF-36 physical functioning score is a well-validated quality of life measure frequently used to assess changes in response to therapeutic interventions in patients with PAD. | change from baseline to month 4.5 follow-up | |
Other | Actigraph-measured physical activity. | The Actigraph will be used to measure physical activity. | change in physical activity from baseline to 4.5 month follow-up | |
Primary | Change in Six-Minute Walk Performance at 9-month follow-up | In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded. | change from baseline to month 9 | |
Secondary | Change in Walking Impairment Questionnaire (WIQ) distance and speed and stair-climbing scores between baseline and nine-month follow-up | The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed. | change from baseline to month 9 follow-up | |
Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS) Questionnaires | PROMIS Physical Function, PROMIS Pain Interference and PROMIS Ability to Participate in Social Roles and Activities questionnaires will be used to assess patient-reported health status for physical, mental, and social well-being. | change from baseline to month 9 follow-up | |
Secondary | Short-Form 36 (SF-36) physical functioning score | The SF-36 physical functioning score is a well-validated quality of life measure frequently used to assess changes in response to therapeutic interventions in patients with PAD. | change from baseline to month 9 follow-up | |
Secondary | Actigraph-measured physical activity. | The Actigraph will be used to measure physical activity. | change in physical activity from baseline to 9 month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05712395 -
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
|
N/A | |
Active, not recruiting |
NCT04534257 -
Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Completed |
NCT02554266 -
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
|
||
Completed |
NCT03921905 -
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
|
||
Not yet recruiting |
NCT06369350 -
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
|
Early Phase 1 | |
Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Completed |
NCT02542267 -
In-Stent Restenosis Post-Approval Study
|
N/A | |
Completed |
NCT02522884 -
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries
|
N/A | |
Completed |
NCT02563535 -
Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT02262949 -
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
Completed |
NCT01743872 -
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
|
N/A | |
Recruiting |
NCT01424020 -
Walking Estimated Limitation Calculated by History - Study 2
|
Phase 4 | |
Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A |